nodes	percent_of_prediction	percent_of_DWPC	metapath
Niacin—SLC22A5—dilated cardiomyopathy	0.684	1	CbGaD
Niacin—SLC22A5—Furosemide—dilated cardiomyopathy	0.122	1	CbGbCtD
Niacin—Glucose tolerance decreased—Furosemide—dilated cardiomyopathy	0.00604	0.0596	CcSEcCtD
Niacin—NNMT—cardiac ventricle—dilated cardiomyopathy	0.0041	0.169	CbGeAlD
Niacin—NNMT—myocardium—dilated cardiomyopathy	0.00385	0.159	CbGeAlD
Niacin—SLC16A3—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.00379	0.0551	CbGpPWpGaD
Niacin—Gastrointestinal symptom NOS—Spironolactone—dilated cardiomyopathy	0.00379	0.0374	CcSEcCtD
Niacin—NNMT—heart—dilated cardiomyopathy	0.00269	0.111	CbGeAlD
Niacin—Breast pain—Spironolactone—dilated cardiomyopathy	0.00255	0.0252	CcSEcCtD
Niacin—NNMT—cardiac atrium—dilated cardiomyopathy	0.0023	0.0952	CbGeAlD
Niacin—SLC16A1—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHA—dilated cardiomyopathy	0.00205	0.0297	CbGpPWpGaD
Niacin—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00205	0.0202	CcSEcCtD
Niacin—Bursitis—Lisinopril—dilated cardiomyopathy	0.00188	0.0186	CcSEcCtD
Niacin—SLC16A3—Basigin interactions—ITGB1—dilated cardiomyopathy	0.00188	0.0273	CbGpPWpGaD
Niacin—SLC16A3—heart—dilated cardiomyopathy	0.00184	0.076	CbGeAlD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00179	0.0261	CbGpPWpGaD
Niacin—SLC16A1—cardiac ventricle—dilated cardiomyopathy	0.0017	0.0703	CbGeAlD
Niacin—SLC16A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00167	0.0243	CbGpPWpGaD
Niacin—SLC16A1—myocardium—dilated cardiomyopathy	0.0016	0.0661	CbGeAlD
Niacin—Cholestasis—Furosemide—dilated cardiomyopathy	0.0016	0.0158	CcSEcCtD
Niacin—SLC5A8—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00156	0.0226	CbGpPWpGaD
Niacin—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00153	0.0151	CcSEcCtD
Niacin—SLC16A3—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.00147	0.0214	CbGpPWpGaD
Niacin—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00142	0.014	CcSEcCtD
Niacin—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00138	0.0136	CcSEcCtD
Niacin—Heartburn—Lisinopril—dilated cardiomyopathy	0.00132	0.0131	CcSEcCtD
Niacin—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00131	0.0129	CcSEcCtD
Niacin—Gout—Furosemide—dilated cardiomyopathy	0.0013	0.0128	CcSEcCtD
Niacin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00129	0.0127	CcSEcCtD
Niacin—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00126	0.0125	CcSEcCtD
Niacin—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00123	0.0122	CcSEcCtD
Niacin—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00123	0.0121	CcSEcCtD
Niacin—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00121	0.0119	CcSEcCtD
Niacin—SLC16A1—heart—dilated cardiomyopathy	0.00112	0.0462	CbGeAlD
Niacin—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00111	0.011	CcSEcCtD
Niacin—Urine output increased—Furosemide—dilated cardiomyopathy	0.0011	0.0108	CcSEcCtD
Niacin—Breast pain—Lisinopril—dilated cardiomyopathy	0.00104	0.0103	CcSEcCtD
Niacin—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.00103	0.0102	CcSEcCtD
Niacin—SLC16A1—Basigin interactions—ITGB1—dilated cardiomyopathy	0.00102	0.0148	CbGpPWpGaD
Niacin—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00101	0.00999	CcSEcCtD
Niacin—Polyuria—Furosemide—dilated cardiomyopathy	0.001	0.0099	CcSEcCtD
Niacin—Cough increased—Lisinopril—dilated cardiomyopathy	0.000993	0.00981	CcSEcCtD
Niacin—Alopecia—Spironolactone—dilated cardiomyopathy	0.000988	0.00976	CcSEcCtD
Niacin—Gout—Lisinopril—dilated cardiomyopathy	0.000974	0.00962	CcSEcCtD
Niacin—SLC22A5—cardiac ventricle—dilated cardiomyopathy	0.000972	0.0402	CbGeAlD
Niacin—SLCO2B1—heart—dilated cardiomyopathy	0.00096	0.0397	CbGeAlD
Niacin—SLC16A1—cardiac atrium—dilated cardiomyopathy	0.000955	0.0395	CbGeAlD
Niacin—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000936	0.00925	CcSEcCtD
Niacin—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00092	0.00909	CcSEcCtD
Niacin—SLC22A5—myocardium—dilated cardiomyopathy	0.000914	0.0378	CbGeAlD
Niacin—SLC16A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000902	0.0131	CbGpPWpGaD
Niacin—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000872	0.00861	CcSEcCtD
Niacin—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000863	0.00853	CcSEcCtD
Niacin—HCAR2—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000856	0.0124	CbGpPWpGaD
Niacin—HCAR2—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000856	0.0124	CbGpPWpGaD
Niacin—Urinary retention—Furosemide—dilated cardiomyopathy	0.000836	0.00826	CcSEcCtD
Niacin—SLC5A8—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000812	0.0118	CbGpPWpGaD
Niacin—HCAR3—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000811	0.0118	CbGpPWpGaD
Niacin—HCAR3—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000811	0.0118	CbGpPWpGaD
Niacin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000803	0.00794	CcSEcCtD
Niacin—Hypertonia—Lisinopril—dilated cardiomyopathy	0.000797	0.00787	CcSEcCtD
Niacin—HCAR2—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000796	0.0116	CbGpPWpGaD
Niacin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000795	0.00785	CcSEcCtD
Niacin—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—SDHA—dilated cardiomyopathy	0.000794	0.0115	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00079	0.0115	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00079	0.0115	CbGpPWpGaD
Niacin—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000776	0.00766	CcSEcCtD
Niacin—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000765	0.00756	CcSEcCtD
Niacin—SLC16A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000759	0.011	CbGpPWpGaD
Niacin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000759	0.0075	CcSEcCtD
Niacin—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.000755	0.00746	CcSEcCtD
Niacin—HCAR3—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000754	0.011	CbGpPWpGaD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000753	0.0109	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000735	0.0107	CbGpPWpGaD
Niacin—Eczema—Lisinopril—dilated cardiomyopathy	0.000734	0.00725	CcSEcCtD
Niacin—Somnolence—Spironolactone—dilated cardiomyopathy	0.000706	0.00698	CcSEcCtD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.0007	0.0102	CbGpPWpGaD
Niacin—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000696	0.00688	CcSEcCtD
Niacin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000686	0.00678	CcSEcCtD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000681	0.00989	CbGpPWpGaD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000681	0.00989	CbGpPWpGaD
Niacin—Arthritis—Lisinopril—dilated cardiomyopathy	0.000679	0.00671	CcSEcCtD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000678	0.00985	CbGpPWpGaD
Niacin—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000655	0.00647	CcSEcCtD
Niacin—Sweating—Furosemide—dilated cardiomyopathy	0.00065	0.00642	CcSEcCtD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000645	0.00937	CbGpPWpGaD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000645	0.00937	CbGpPWpGaD
Niacin—SLC22A5—heart—dilated cardiomyopathy	0.000638	0.0264	CbGeAlD
Niacin—Face oedema—Lisinopril—dilated cardiomyopathy	0.000637	0.00629	CcSEcCtD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000633	0.00919	CbGpPWpGaD
Niacin—Urticaria—Spironolactone—dilated cardiomyopathy	0.000631	0.00624	CcSEcCtD
Niacin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000628	0.00621	CcSEcCtD
Niacin—SLC16A3—Cell surface interactions at the vascular wall—ITGB1—dilated cardiomyopathy	0.000626	0.00909	CbGpPWpGaD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000613	0.0089	CbGpPWpGaD
Niacin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000603	0.00595	CcSEcCtD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.0006	0.00871	CbGpPWpGaD
Niacin—Visual impairment—Furosemide—dilated cardiomyopathy	0.000586	0.00579	CcSEcCtD
Niacin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000585	0.00578	CcSEcCtD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000581	0.00844	CbGpPWpGaD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000579	0.00841	CbGpPWpGaD
Niacin—QPRT—Metabolism—ANKRD1—dilated cardiomyopathy	0.000574	0.00834	CbGpPWpGaD
Niacin—Influenza—Lisinopril—dilated cardiomyopathy	0.00057	0.00563	CcSEcCtD
Niacin—Eye disorder—Furosemide—dilated cardiomyopathy	0.000569	0.00562	CcSEcCtD
Niacin—Tinnitus—Furosemide—dilated cardiomyopathy	0.000567	0.0056	CcSEcCtD
Niacin—Pruritus—Spironolactone—dilated cardiomyopathy	0.000562	0.00555	CcSEcCtD
Niacin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000556	0.00549	CcSEcCtD
Niacin—Angiopathy—Furosemide—dilated cardiomyopathy	0.000552	0.00545	CcSEcCtD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000549	0.00798	CbGpPWpGaD
Niacin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000549	0.00542	CcSEcCtD
Niacin—SLC22A5—cardiac atrium—dilated cardiomyopathy	0.000546	0.0226	CbGeAlD
Niacin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000544	0.00537	CcSEcCtD
Niacin—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000544	0.00537	CcSEcCtD
Niacin—QPRT—Metabolism—TAZ—dilated cardiomyopathy	0.00054	0.00785	CbGpPWpGaD
Niacin—NNMT—Metabolism—ANKRD1—dilated cardiomyopathy	0.000534	0.00776	CbGpPWpGaD
Niacin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00053	0.00523	CcSEcCtD
Niacin—Erythema—Furosemide—dilated cardiomyopathy	0.00053	0.00523	CcSEcCtD
Niacin—Dizziness—Spironolactone—dilated cardiomyopathy	0.000525	0.00519	CcSEcCtD
Niacin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000525	0.00519	CcSEcCtD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000523	0.0076	CbGpPWpGaD
Niacin—Flatulence—Furosemide—dilated cardiomyopathy	0.000522	0.00516	CcSEcCtD
Niacin—HCAR2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000518	0.00753	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000518	0.00753	CbGpPWpGaD
Niacin—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000509	0.00503	CcSEcCtD
Niacin—Vomiting—Spironolactone—dilated cardiomyopathy	0.000505	0.00499	CcSEcCtD
Niacin—NNMT—Metabolism—TAZ—dilated cardiomyopathy	0.000502	0.00729	CbGpPWpGaD
Niacin—Rash—Spironolactone—dilated cardiomyopathy	0.000501	0.00495	CcSEcCtD
Niacin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000501	0.00494	CcSEcCtD
Niacin—Vision blurred—Furosemide—dilated cardiomyopathy	0.000499	0.00493	CcSEcCtD
Niacin—Headache—Spironolactone—dilated cardiomyopathy	0.000498	0.00492	CcSEcCtD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000497	0.00721	CbGpPWpGaD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000496	0.00721	CbGpPWpGaD
Niacin—Jaundice—Lisinopril—dilated cardiomyopathy	0.000496	0.0049	CcSEcCtD
Niacin—HCAR3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000491	0.00714	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000491	0.00714	CbGpPWpGaD
Niacin—QPRT—Metabolism—SDHA—dilated cardiomyopathy	0.000488	0.0071	CbGpPWpGaD
Niacin—Sweating—Lisinopril—dilated cardiomyopathy	0.000488	0.00482	CcSEcCtD
Niacin—HCAR2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000482	0.007	CbGpPWpGaD
Niacin—Vertigo—Furosemide—dilated cardiomyopathy	0.000476	0.0047	CcSEcCtD
Niacin—Leukopenia—Furosemide—dilated cardiomyopathy	0.000474	0.00468	CcSEcCtD
Niacin—Nausea—Spironolactone—dilated cardiomyopathy	0.000472	0.00466	CcSEcCtD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000471	0.00684	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000467	0.00678	CbGpPWpGaD
Niacin—HCAR2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000463	0.00673	CbGpPWpGaD
Niacin—SLCO2B1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000462	0.00671	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—TTN—dilated cardiomyopathy	0.000458	0.00666	CbGpPWpGaD
Niacin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000458	0.00452	CcSEcCtD
Niacin—HCAR3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000457	0.00664	CbGpPWpGaD
Niacin—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000457	0.00451	CcSEcCtD
Niacin—NNMT—Metabolism—SDHA—dilated cardiomyopathy	0.000454	0.0066	CbGpPWpGaD
Niacin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00045	0.00444	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000448	0.00442	CcSEcCtD
Niacin—HCAR3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000442	0.00643	CbGpPWpGaD
Niacin—Dry mouth—Furosemide—dilated cardiomyopathy	0.000441	0.00436	CcSEcCtD
Niacin—HCAR3—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000439	0.00638	CbGpPWpGaD
Niacin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000432	0.00427	CcSEcCtD
Niacin—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000426	0.00421	CcSEcCtD
Niacin—Shock—Furosemide—dilated cardiomyopathy	0.000425	0.0042	CcSEcCtD
Niacin—Flushing—Lisinopril—dilated cardiomyopathy	0.000424	0.00419	CcSEcCtD
Niacin—Skin disorder—Furosemide—dilated cardiomyopathy	0.00042	0.00415	CcSEcCtD
Niacin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000418	0.00413	CcSEcCtD
Niacin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000414	0.00409	CcSEcCtD
Niacin—Anorexia—Furosemide—dilated cardiomyopathy	0.000412	0.00407	CcSEcCtD
Niacin—SLC16A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00041	0.00596	CbGpPWpGaD
Niacin—Chills—Lisinopril—dilated cardiomyopathy	0.00041	0.00405	CcSEcCtD
Niacin—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000408	0.00403	CcSEcCtD
Niacin—Hypotension—Furosemide—dilated cardiomyopathy	0.000404	0.00399	CcSEcCtD
Niacin—Alopecia—Lisinopril—dilated cardiomyopathy	0.000403	0.00399	CcSEcCtD
Niacin—HCAR2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000399	0.00579	CbGpPWpGaD
Niacin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000397	0.00393	CcSEcCtD
Niacin—Erythema—Lisinopril—dilated cardiomyopathy	0.000397	0.00393	CcSEcCtD
Niacin—SLC16A3—Hemostasis—ACTN2—dilated cardiomyopathy	0.000397	0.00577	CbGpPWpGaD
Niacin—SLC16A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000397	0.00576	CbGpPWpGaD
Niacin—Flatulence—Lisinopril—dilated cardiomyopathy	0.000392	0.00387	CcSEcCtD
Niacin—Tension—Lisinopril—dilated cardiomyopathy	0.00039	0.00385	CcSEcCtD
Niacin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000388	0.00383	CcSEcCtD
Niacin—Nervousness—Lisinopril—dilated cardiomyopathy	0.000386	0.00381	CcSEcCtD
Niacin—SLC16A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000386	0.00561	CbGpPWpGaD
Niacin—SLC16A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000386	0.00561	CbGpPWpGaD
Niacin—Somnolence—Furosemide—dilated cardiomyopathy	0.000384	0.0038	CcSEcCtD
Niacin—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000382	0.00377	CcSEcCtD
Niacin—HCAR2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000378	0.00549	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000378	0.00549	CbGpPWpGaD
Niacin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000376	0.00371	CcSEcCtD
Niacin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000375	0.0037	CcSEcCtD
Niacin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000373	0.00369	CcSEcCtD
Niacin—Pain—Furosemide—dilated cardiomyopathy	0.00037	0.00365	CcSEcCtD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000368	0.00535	CbGpPWpGaD
Niacin—Angioedema—Lisinopril—dilated cardiomyopathy	0.000363	0.00359	CcSEcCtD
Niacin—SLC16A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000359	0.00521	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000358	0.00521	CbGpPWpGaD
Niacin—Vertigo—Lisinopril—dilated cardiomyopathy	0.000357	0.00353	CcSEcCtD
Niacin—Syncope—Lisinopril—dilated cardiomyopathy	0.000356	0.00352	CcSEcCtD
Niacin—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000356	0.00351	CcSEcCtD
Niacin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000354	0.00349	CcSEcCtD
Niacin—Palpitations—Lisinopril—dilated cardiomyopathy	0.000351	0.00347	CcSEcCtD
Niacin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000349	0.00345	CcSEcCtD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000349	0.00507	CbGpPWpGaD
Niacin—Cough—Lisinopril—dilated cardiomyopathy	0.000347	0.00343	CcSEcCtD
Niacin—Urticaria—Furosemide—dilated cardiomyopathy	0.000343	0.00339	CcSEcCtD
Niacin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000342	0.00338	CcSEcCtD
Niacin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000342	0.00338	CcSEcCtD
Niacin—Myalgia—Lisinopril—dilated cardiomyopathy	0.000338	0.00334	CcSEcCtD
Niacin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000338	0.00334	CcSEcCtD
Niacin—SLC16A3—Hemostasis—VCL—dilated cardiomyopathy	0.000338	0.00491	CbGpPWpGaD
Niacin—SLC16A1—Cell surface interactions at the vascular wall—ITGB1—dilated cardiomyopathy	0.000338	0.00491	CbGpPWpGaD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000336	0.00332	CcSEcCtD
Niacin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000331	0.00327	CcSEcCtD
Niacin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000324	0.0032	CcSEcCtD
Niacin—Oedema—Lisinopril—dilated cardiomyopathy	0.000324	0.0032	CcSEcCtD
Niacin—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000321	0.00467	CbGpPWpGaD
Niacin—Shock—Lisinopril—dilated cardiomyopathy	0.000319	0.00315	CcSEcCtD
Niacin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000319	0.00315	CcSEcCtD
Niacin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000317	0.00313	CcSEcCtD
Niacin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000315	0.00311	CcSEcCtD
Niacin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000314	0.0031	CcSEcCtD
Niacin—Asthenia—Furosemide—dilated cardiomyopathy	0.00031	0.00306	CcSEcCtD
Niacin—Anorexia—Lisinopril—dilated cardiomyopathy	0.000309	0.00305	CcSEcCtD
Niacin—Pruritus—Furosemide—dilated cardiomyopathy	0.000306	0.00302	CcSEcCtD
Niacin—Hypotension—Lisinopril—dilated cardiomyopathy	0.000303	0.00299	CcSEcCtD
Niacin—QPRT—Disease—NPPA—dilated cardiomyopathy	0.000299	0.00434	CbGpPWpGaD
Niacin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000296	0.00292	CcSEcCtD
Niacin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000296	0.00292	CcSEcCtD
Niacin—Insomnia—Lisinopril—dilated cardiomyopathy	0.000293	0.0029	CcSEcCtD
Niacin—HCAR2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000293	0.00426	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000293	0.00426	CbGpPWpGaD
Niacin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000291	0.00288	CcSEcCtD
Niacin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000289	0.00286	CcSEcCtD
Niacin—QPRT—Disease—PSEN2—dilated cardiomyopathy	0.000289	0.0042	CbGpPWpGaD
Niacin—Somnolence—Lisinopril—dilated cardiomyopathy	0.000288	0.00285	CcSEcCtD
Niacin—Dizziness—Furosemide—dilated cardiomyopathy	0.000286	0.00282	CcSEcCtD
Niacin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000286	0.00282	CcSEcCtD
Niacin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000282	0.00279	CcSEcCtD
Niacin—HCAR2—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00028	0.00407	CbGpPWpGaD
Niacin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00028	0.00277	CcSEcCtD
Niacin—HCAR3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000278	0.00403	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000278	0.00403	CbGpPWpGaD
Niacin—Pain—Lisinopril—dilated cardiomyopathy	0.000277	0.00274	CcSEcCtD
Niacin—Vomiting—Furosemide—dilated cardiomyopathy	0.000275	0.00272	CcSEcCtD
Niacin—Rash—Furosemide—dilated cardiomyopathy	0.000273	0.00269	CcSEcCtD
Niacin—Dermatitis—Furosemide—dilated cardiomyopathy	0.000272	0.00269	CcSEcCtD
Niacin—HCAR2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000272	0.00396	CbGpPWpGaD
Niacin—Headache—Furosemide—dilated cardiomyopathy	0.000271	0.00268	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000266	0.00386	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000266	0.00386	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000266	0.00386	CbGpPWpGaD
Niacin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000265	0.00262	CcSEcCtD
Niacin—HCAR2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000264	0.00383	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—ANKRD1—dilated cardiomyopathy	0.000261	0.00379	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000258	0.00375	CbGpPWpGaD
Niacin—Urticaria—Lisinopril—dilated cardiomyopathy	0.000258	0.00255	CcSEcCtD
Niacin—Nausea—Furosemide—dilated cardiomyopathy	0.000257	0.00254	CcSEcCtD
Niacin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000256	0.00253	CcSEcCtD
Niacin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000256	0.00253	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000252	0.00366	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000252	0.00366	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00025	0.00363	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—TTN—dilated cardiomyopathy	0.000247	0.0036	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000247	0.00359	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—TAZ—dilated cardiomyopathy	0.000245	0.00356	CbGpPWpGaD
Niacin—SLCO2B1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000241	0.0035	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000239	0.00348	CbGpPWpGaD
Niacin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000239	0.00236	CcSEcCtD
Niacin—SLCO2B1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000235	0.00341	CbGpPWpGaD
Niacin—SLCO2B1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000235	0.00341	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000234	0.00341	CbGpPWpGaD
Niacin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000233	0.0023	CcSEcCtD
Niacin—Pruritus—Lisinopril—dilated cardiomyopathy	0.000229	0.00227	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000227	0.0033	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000225	0.00327	CbGpPWpGaD
Niacin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000222	0.00219	CcSEcCtD
Niacin—SLC16A3—Metabolism—SDHA—dilated cardiomyopathy	0.000222	0.00322	CbGpPWpGaD
Niacin—SLCO2B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000218	0.00317	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—ACTN2—dilated cardiomyopathy	0.000215	0.00312	CbGpPWpGaD
Niacin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000214	0.00212	CcSEcCtD
Niacin—SLC16A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000214	0.00311	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000214	0.0031	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000214	0.0031	CbGpPWpGaD
Niacin—SLC16A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000208	0.00303	CbGpPWpGaD
Niacin—SLC16A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000208	0.00303	CbGpPWpGaD
Niacin—Vomiting—Lisinopril—dilated cardiomyopathy	0.000206	0.00204	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000205	0.00297	CbGpPWpGaD
Niacin—Rash—Lisinopril—dilated cardiomyopathy	0.000205	0.00202	CcSEcCtD
Niacin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000204	0.00202	CcSEcCtD
Niacin—Headache—Lisinopril—dilated cardiomyopathy	0.000203	0.00201	CcSEcCtD
Niacin—HCAR3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000203	0.00294	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000194	0.00282	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000194	0.00282	CbGpPWpGaD
Niacin—SLC16A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000194	0.00281	CbGpPWpGaD
Niacin—Nausea—Lisinopril—dilated cardiomyopathy	0.000193	0.0019	CcSEcCtD
Niacin—SLC22A5—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000184	0.00268	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000184	0.00267	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—VCL—dilated cardiomyopathy	0.000182	0.00265	CbGpPWpGaD
Niacin—SLC22A5—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000179	0.0026	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000177	0.00257	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—ITGB1—dilated cardiomyopathy	0.00017	0.00246	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000168	0.00244	CbGpPWpGaD
Niacin—SLC22A5—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000167	0.00242	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000166	0.00241	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.00016	0.00233	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000158	0.0023	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000157	0.00228	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000157	0.00228	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000157	0.00228	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000151	0.00219	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00015	0.00218	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000149	0.00216	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000149	0.00216	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000146	0.00212	CbGpPWpGaD
Niacin—QPRT—Disease—RAC1—dilated cardiomyopathy	0.000145	0.00211	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—CD36—dilated cardiomyopathy	0.000145	0.0021	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000144	0.00209	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000143	0.00207	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000141	0.00206	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000141	0.00205	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000138	0.00201	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000136	0.00198	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—RAC1—dilated cardiomyopathy	0.000136	0.00198	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000134	0.00195	CbGpPWpGaD
Niacin—QPRT—Metabolism—GPX1—dilated cardiomyopathy	0.000133	0.00193	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—TAZ—dilated cardiomyopathy	0.000132	0.00192	CbGpPWpGaD
Niacin—QPRT—Metabolism—CD36—dilated cardiomyopathy	0.000129	0.00188	CbGpPWpGaD
Niacin—NNMT—Metabolism—GPX1—dilated cardiomyopathy	0.000123	0.00179	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000121	0.00176	CbGpPWpGaD
Niacin—NNMT—Metabolism—CD36—dilated cardiomyopathy	0.00012	0.00175	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—SDHA—dilated cardiomyopathy	0.00012	0.00174	CbGpPWpGaD
Niacin—QPRT—Metabolism—AGT—dilated cardiomyopathy	0.000116	0.00169	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000115	0.00167	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000115	0.00166	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000109	0.00158	CbGpPWpGaD
Niacin—NNMT—Metabolism—AGT—dilated cardiomyopathy	0.000108	0.00157	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.99e-05	0.00145	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.85e-05	0.00143	CbGpPWpGaD
Niacin—QPRT—Disease—RAF1—dilated cardiomyopathy	9.64e-05	0.0014	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.47e-05	0.00138	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.34e-05	0.00136	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—ITGB1—dilated cardiomyopathy	9.16e-05	0.00133	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—RAF1—dilated cardiomyopathy	9.04e-05	0.00131	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—RAC1—dilated cardiomyopathy	8.9e-05	0.00129	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—AGT—dilated cardiomyopathy	8.5e-05	0.00124	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—RAC1—dilated cardiomyopathy	8.44e-05	0.00123	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—AGT—dilated cardiomyopathy	8.06e-05	0.00117	CbGpPWpGaD
Niacin—SLC16A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.83e-05	0.00114	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—CD36—dilated cardiomyopathy	7.81e-05	0.00114	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—RAC1—dilated cardiomyopathy	7.36e-05	0.00107	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.85e-05	0.000995	CbGpPWpGaD
Niacin—QPRT—Disease—EGFR—dilated cardiomyopathy	6.61e-05	0.00096	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.49e-05	0.000943	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—GPX1—dilated cardiomyopathy	6.02e-05	0.000875	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—RAF1—dilated cardiomyopathy	5.9e-05	0.000857	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—CD36—dilated cardiomyopathy	5.87e-05	0.000852	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—RAF1—dilated cardiomyopathy	5.59e-05	0.000813	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—AGT—dilated cardiomyopathy	5.28e-05	0.000767	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—RAF1—dilated cardiomyopathy	4.88e-05	0.000709	CbGpPWpGaD
Niacin—SLCO2B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.76e-05	0.000691	CbGpPWpGaD
Niacin—SLC16A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.23e-05	0.000614	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—EGFR—dilated cardiomyopathy	4.05e-05	0.000588	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.92e-05	0.00057	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—EGFR—dilated cardiomyopathy	3.84e-05	0.000557	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	3.69e-05	0.000536	CbGpPWpGaD
Niacin—SLC22A5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.63e-05	0.000528	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.34e-05	0.000485	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—GPX1—dilated cardiomyopathy	3.25e-05	0.000473	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—CD36—dilated cardiomyopathy	3.17e-05	0.00046	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—AGT—dilated cardiomyopathy	2.85e-05	0.000414	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	9.06e-06	0.000132	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	8.82e-06	0.000128	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	7.94e-06	0.000115	CbGpPWpGaD
